Introduction
Mirikizumab (miri) achieved early and sustained symptom control in patients (pts) with ulcerative colitis (UC) in the Phase 3, randomized, double-blind, placebo-controlled induction study (LUCENT-1; NCT03518086) at Week (W)12, through W40 of maintenance treatment (W52 of continuous therapy) in LUCENT-2 (NCT03524092). Beyond symptom relief, an international Delphi consensus defines components of comprehensive disease control (CDC) as a composite measure of individual patient benefit.1 We evaluated two possible definitions of CDC at W52, each informed by this consensus, among pts who achieved clinical response with miri at W12.
Aims & Methods
W12 induction clinical responders to intravenous miri 300mg every 4W (Q4W) from LUCENT-1 who entered LUCENT-2 (N=544) were re-randomized 2:1 to subcutaneous miri 200mg (n=365) or placebo (PBO) Q4W (n=179). The proportions of pts achieving CDC at W52 were evaluated separately among overall, biologic (bio)-failed and non-bio-failed pts as per two definitions: CDC1 (clinical remission [PRO-2 + endoscopy]¶ + no steroid use for ≥12W + histologic remission§ + fecal calprotectin ≤250μg/g), and CDC2 (CDC1 + Inflammatory Bowel Disease Questionnaire [IBDQ] remission¥). Subgroup analyses among non-bio-failed pts were conducted by baseline disease characteristics. IBDQ remission based on CDC1 achievement at W52 was compared among miri-treated pts. Missing data were handled using non-responder imputation.
Results
At W52, significantly more pts receiving miri vs. PBO (miri withdrawal) achieved CDC1 (27.7% vs. 14.0%; p<0.05) and CDC2 (25.2% vs. 12.3%; p<0.05), regardless of prior bio-failure status. Both CDC rates were numerically higher in non-bio-failed miri-treated pts. When assessing subgroup efficacy in non-bio-failed miri-treated pts by baseline characteristics, only disease duration differed significantly for CDC2 (<7 years vs. ≥7 years: 32.2% vs. 18.2%; p<0.05). Among miri-treated pts, majority of CDC1 achievers also met criteria for CDC2 (achieved IBDQ remission) at W52 (91.1% vs. 65.2% in CDC1 non-achievers; p<0.001).
Table 1: Proportion of patients achieving CDC at Week 52 (Miri induction respondersa)
| Patient Populations | CDC1b, n/N (%) Miri | CDC1b, n/N (%) PBO | p-value vs PBOc | p-value between Miri subgroups:d CDC1b | CDC2e, n/N (%) Miri | CDC2e, n/N (%) PBO | p-value vs PBOc | p-value between Miri subgroups:d CDC2c |
|
| Overall | 101/365(27.7) | 25/179(14.0) | 0.002 | - | 92/365(25.2) | 22/179(12.3) | 0.002 | - |
|
| Bio-failed | 30/128(23.4) | 6/64(9.4) | 0.019 | 0.184 | 25/128(19.5) | 5/64(7.8) | 0.037 | 0.067 |
|
| Non-bio-failed | 71/237(30.0) | 19/115(16.5) | 0.027 | 67/237(28.3) | 17/115(14.8) | 0.022 |
|
Non-bio-failed Subgroups | Baseline UC duration | <7 years ≥7 years | 57/171(33.3) 14/66(21.2) | 10/76(13.2) 9/39(23.1) | 0.004 0.586 | 0.068 | 55/171(32.2) 12/66(18.2) | 9/76(11.8) 8/39(20.5) | 0.004 0.554 | 0.032 |
|
Baseline mMS | 4-6 7-9 | 37/125(29.6) 34/112(30.4) | 10/49(20.4) 9/66(13.6) | 0.560 0.023 | 0.899 | 35/125(28.0) 32/112(28.6) | 9/49(18.4) 8/66(12.1) | 0.497 0.023 | 0.922 |
|
Baseline ES | ES=2 ES=3 | 28/95(29.5) 43/142(30.3) | 10/57(17.5) 9/58(15.5) | 0.501 0.023 | 0.894 | 26/95(27.4) 41/142(28.9) | 9/57(15.8) 8/58(13.8) | 0.408 0.021 | 0.801 |
|
UC location | Left-sided f Pancolitis | 50/158(31.6) 21/79(26.6) | 15/75(20.0) 4/40(10.0) | 0.084 0.076 | 0.422 | 47/158(29.7) 20/79(25.3) | 14/75(18.7) 3/40(7.5) | 0.093 0.048 | 0.475 |
|
Data are based on non-responder imputation (NRI). aMiri induction responders: Patients who had clinical response to miri at Week 12 of LUCENT-1 (decrease in the modified Mayo score of ≥2 points and ≥30% decrease from baseline (BL); and decrease of ≥1 point in the Rectal Bleeding (RB) subscore from BL or a RB score of 0 or 1) after receiving 300mg IV miri every 4 weeks for 12 weeks. bCDC1 = clinical remission + no corticosteroid use for ≥12 weeks prior to Week 52 + histologic remission + fecal calprotectin ≤250 μg/g cp-value is from Cochran-Mantel-Haenszel (CMH) test adjusted by prior biologic or tofacitinib failure (yes/no), corticosteroid use (yes/no) at LUCENT-1 baseline, region (North America/Europe/Other), Clinical Remission status (yes/no) at LUCENT-1 Week 12. dp-value is from Pearson chi-square test comparing response rates between subgroups among Miri-treated patients eCDC2 = CDC1 + IBDQ remission fIncluding a small number of patients with proctitis. - No subgroup data Definitions ¶ Clinical remission: Stool frequency subscore = 0 or 1 with a ≥1-point decrease from baseline, and rectal bleeding subscore = 0, and endoscopic subscore = 0 or 1 (excluding friability) § Histologic remission: Defined per the LUCENT histopathology charter as absence of neutrophilic inflammation: Geboes score ≤2B.0, with subscores of 0 for grades 2b (neutrophils in lamina propria), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration). ¥ IBDQ remission: IBDQ total score ≥170 Bio-failed: Patients with a prior inadequate response, loss of response, or intolerance to biologic therapy or Janus kinase inhibitors (tofacitinib) at LUCENT-1 induction baseline. Non-bio-failed: Patients who did not meet the biologic failed definition for whom, however, a conventional therapy such as immunomodulators or corticosteroids had failed as of LUCENT-1 induction baseline. Abbreviations Bio=biologic; CDC=comprehensive disease control; ES=endoscopic index of severity; IBDQ=inflammatory bowel disease questionnaire; Miri=mirikizumab; mMS=modified mayo score; N=number of patients in the analysis population; n=number of patients in the specified subgroup; PBO=placebo; UC=ulcerative colitis |
Conclusion
Miri enables clinically meaningful CDC achievement after one year of treatment in moderately-to-severely active UC. The consistency of miri treatment effect across both CDC definitions regardless of prior bio-failure status, and the strong association of CDC1 with improved quality of life, collectively support a patient-centred, treat-to-target approach beyond clinical remission.
References
1. Schreiber S, et al. J Crohns Colitis. 2024;91–105
Disclosure
Stefan Schreiber: consultant/speaker fees from AbbVie, Allergosan, Amgen, Arena, BMS, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, Genentech (Roche), GSK, IMAB, Janssen, Eli Lilly, MSD, Pfizer, Shire, Takeda, and Ventyx.
Fernando Magro: speaker for AbbVie, Arena Pharmaceuticals, Biogen, Bristol Myers Squibb, Eli Lilly and Company, Dr Falk Pharma, Ferring Pharmaceuticals, Hospira, Janssen, Laboratórios Vitoria, Merck Sharp & Dohme, Pfizer, Sandoz, Takeda, UCB Pharma, and Vifor.
Silvio Danese: reports consulting fees from AbbVie, Alimentiv, Allergan, Amgen, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly and Company, Enthera, Ferring Pharmaceuticals, Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB, Vial, and Vifor; and lecture fees from AbbVie, Amgen, Ferring Pharmaceuticals, Gilead, Janssen, Mylan, Pfizer, and Takeda.
Taku Kobayashi: reports serving as an advisory board member, consultant, or speaker for AbbVie GK, Alfresa Pharma Corporation, Alimentiv, Bristol Myers Squibb, Celltrion, Covidien, EA Pharma, Eli Lilly Japan K.K., Ferring Pharmaceuticals, Galapagos, Gilead Sciences, Janssen Pharmaceutical K.K., JIMRO, Kissei Pharmaceutical, Kowa, Kyorin Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Mochida Pharmaceutical, MSD, Nippon Kayaku, Pfizer Japan Inc, Sanofi, Sekisui Medical, Spyre, Takeda Pharmaceutical, TOPPAN Holdings, and Zeria Pharmaceutical and receiving research funding from AbbVie GK, Alfresa Pharma Corporation, Bristol Myers Squibb, EA Pharma, Gilead Sciences, Helmsley Charitable Trust, JIMRO, Kyorin Pharmaceutical, Miyarisan Pharmaceutical, Mochida Pharmaceutical, Nippon Kayaku, Pfizer Japan Inc, Sekisui Medical, Samsung Electronics, Takeda Pharmaceutical, and Zeria Pharmaceutical.
Zhihua Ran: investigator of LUCENT-2 study.
Christina Ha: consultant/advisory board of AbbVie, Bristol Myers Squibb, Genentech, InDex Pharmaceuticals, Janssen, Takeda, Pfizer; received grant support from: Pfizer; received research support from: Pfizer, Eli Lilly and Company, Genentech.
Edward Barnes: received consulting fees from: AbbVie, Boomerang Medical, Bristol Myers Squibb, Direct Biologics, Eli Lilly and Company, Pfizer, Sanofi, and Target RWE.
Aline Charabaty: received advisory board fees and/or consultancy fees and/or received educational grants from: AbbVie, Eli Lilly and Company, Janssen, Pfizer, and Takeda.
Dominik Bettenworth: served as advisory board member or consultant for: AbbVie, Alfasigma, Amgen, Arena Pharmaceuticals, Art tempi, BNG Service GmbH, Bristol Myers Squibb, CED-Service GmbH, Celltrion, DGVS, Diaplan, Doctorflix, Eli Lilly and Company, Else Kröner-Fresenius Foundation, Falk Foundation, Ferring Pharmaceuticals, Fresenius, Galapagos NV, Gastro Today, GlaxoSmithKline, Guidepoint, Hexal Pharmaceuticals, Impulze, Janssen Cilag, Medical Tribune, MedTrix Healthcare, Merck Sharp & Dohme, Mylan, Onkowissen, Pfizer, Pharmacosmos, Roche, Sandoz, STADA, StreamedUp, Takeda, Tetrameros, Thieme Group, Tillotts Pharma, UCB, Viatris, and Vifor Pharma.
Sebastian Maier, Isabel Redondo, Karim Ben Mahfoudh, Yajie Duan: employees and stockholders at Eli Lilly and Company.
David T. Rubin: received grants or contracts from: Takeda; received consulting fees from: AbbVie, Abivax, AltruBio, Athos Therapeutics, Bristol Myers Squibb, Celltrion, Connect BioPharma, Eli Lilly and Company, Genentech/Roche, Iterative Health, Janssen, Johnson & Johnson, Merck, Mirador Therapeutics, Odyssey Therapeutics, Pfizer, Sanofi, Spyre Therapeutics, Takeda, Vedanta Biosciences and Ventyx Biosciences.